Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab versus Rituximab in children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome
2015-000624-28Phase 2Completed
- Sponsor
- Istituto Giannina Gaslini
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Idiopathic nephrotic syndrome (INS) comparing Ofatumumab arm with Rituximab arm (2 arms). Primary endpoint: Risk of relapse at 12 months without steroid or calcineurin inhibitors. Started Nov 2020; status: completed.
02
Drugs
ofatumumabrituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on 2015-000624-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000624-28.